Abstract:Mouse models are the basis of preclinical and translational research in solid tumors. Multiple methods exist to induce tumor formation in mice, including genetically engineered mouse models, chemotoxic agents, injection of tumor cells, and xenograft approaches. Synovial sarcoma, a rare highly malignant soft-tissue tumor, poses a serious threat to patients due to its aggressive nature and associated high rates of mortality and morbidity. This disease's underlying cause and development remain poorly comprehended, and existing treatment approaches have yielded unsatisfactory outcomes. In the last two decades, numerous effective animal models of soft tissue sarcoma (STS) have been created, primarily utilizing genetically engineered mice and zebrafish, however long latency of tumor development for several months in these models creates a barrier for practical in-vivo experiments for drug testing or manipulating the cellular composition of the tumor microenvironment. In studying cancer immunotherapy, it is important to consider aspects of antitumor immune responses and to produce a model that mimics the complexity of the immune system We have generated a new mouse model of synovial sarcoma of exceptionally fast tumor development. Intramuscular delivery of Cre recombinase protein in mice which drives conditional knockdown in PTEN, stabilization of β-catenin, and formation of fusion oncogenes of SS18-SSX2 was sufficient to initiate high-grade synovial sarcomas with myofibroblastic differentiation in 3 weeks. As immunotherapy is increasingly applied to sarcomas, our mouse model will serve as a great tool for preclinical data. Flow cytometry-based analysis of peripheral blood shows significant changes in immune cell populations as early as five days after Tat-Cre injection and continues throughout the development of synovial sarcoma. These results suggest a significant systemic phenotypic alteration of circulating immune cells, which may impact other major organs in this genetic mouse model of synovial sarcoma. Single- cell RNA sequencing of the CD45+ leukocytes in the tumor microenvironment reveals subsets that may promote tumor progression. Our work promises to significantly enhance our understanding of the pathogenesis of this disease and establish a reliable preclinical platform for devising and assessing therapeutic interventions. Citation Format: Hesham Mohei, Donn Van Deren, Irene S. Molina, Malay Haldar. New insights from a novel mouse model of synovial sarcoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer; 2024 Nov 17-20; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2024;84(22_Suppl) nr C008.

Cell-of-origin epigenome underlies SS18::SSX-mediated transformation

Synovial Sarcoma Chromatin Dynamics Reveal a Continuum in SS18:SSX Reprograming

SS18::SSX redistributes BAF chromatin remodelers selectively to activate and repress transcription

The chromatin landscape of primary synovial sarcoma organoids is linked to specific epigenetic mechanisms and dependencies

Systematic Transcriptome Analysis of Synovial Sarcoma Reveals Novel Transcriptional And Post-Transcriptional Abnormalities

The Effect of SYT-SSX and Extracellular Signal-Regulated Kinase (ERK) on Cell Proliferation in Synovial Sarcoma

SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma

SYT-SSX1 enhances the invasiveness and maintains stem-like cell properties in synovial sarcoma via induction of TGF-β1/Smad signaling

Novel characteristics for immunophenotype, FISH pattern and molecular cytogenetics in synovial sarcoma

Transcriptomic Profiling of Synovial Sarcoma Reveals Novel Transcriptional and Post-Transcriptional Abnormalities

Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial Sarcoma

The Clinical Implication of SS18 -SSX Fusion Gene in Synovial Sarcoma

Co-existence of SYT-SSX1 and SYT-SSX2 fusions in synovial sarcomas.

Syt-Ssx Is Critical For Cyclin D1 Expression In Synovial Sarcoma Cells: A Gain Of Function Of The T(X;18)(P11.2;Q11.2) Translocation

Molecular Profiling Defines Three Subtypes of Synovial Sarcoma

Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Abstract C008: New insights from a novel mouse model of synovial sarcoma

Identification of Potential Mutations and Genomic Alterations in the Epithelial and Spindle Cell Components of Biphasic Synovial Sarcomas Using a Human Exome SNP Chip

Matrix Metalloproteinase-14 Induces Epithelial-to-mesenchymal Transition in Synovial Sarcoma

The Classification of SYT-SSX Fusion Genes in Synovial Sarcoma and the Correlation between the Type of Fusion Genes and Cell Cycle

Condensate remodeling reorganizes innate SS18 in synovial sarcomagenesis